Download Files:
BRD5529
$110 – $850
Products Details
Product Description
– BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC)[1][2].
Web ID
– HY-115497
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C25H31N5O4
References
– [1]Leshchiner ES, et al. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatorybowel disease. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11392-11397.|[2]Theodore J Kottom, et al. Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9. Drugs R D. 2022 Jun;22(2):165-173.
CAS Number
– 1358488-78-4
Molecular Weight
– 465.54
Compound Purity
– 98.42
SMILES
– O=C(C1=CC(NC(C2=CC=C(C)C=C2)=O)=CN=C1N3CCC(N4CCCCC4)(C(N)=O)CC3)O
Clinical Information
– No Development Reported
Research Area
– Infection; Inflammation/Immunology
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– E1/E2/E3 Enzyme
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
